CliffBio
small molecule

EMEND

APREPITANT

Loss of exclusivitySeptember 2027latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug detail

Brand nameEMEND
Active ingredientAPREPITANT
Strength125MG/KIT
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2015
Marketing statusRX

Listed patents

PatentExpiresType
8258132September 2027product

More from MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EMEND patent cliff — loss of exclusivity September 2027 | CliffBio